FDA label
What is liraglutide used for?
The FDA-approved uses of liraglutide, quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular dise...”
Run it in Rivvi
Which 2027 plans near you dropped or restricted liraglutide?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Liraglutide, injection, solution
Indications and Usage, quoted from the label by Orbicular Pharmaceutical Technologies Private Limited (ANDA217590). Cross-references to other label sections are left out.
Liraglutide injection is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.
Limitations of Use:
Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended.
Source: DailyMed label, set id bb66a46c-9019-4a98-8e5d-581109facfba, version 2, effective October 15, 2026. NDC 81607-018, one of 10 listings for this product.
Liraglutide, injection
Indications and Usage, quoted from the label by Hikma Pharmaceuticals USA Inc. (ANDA215503). Cross-references to other label sections are left out.
Liraglutide injection is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus
Limitations of Use:
Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended.
Source: DailyMed label, set id 2100ec49-57b2-4330-ab5f-057ce9b7e4d0, version 7, effective May 14, 2026. NDC 0143-9144, one of 5 listings for this product.
Questions
What is liraglutide used for?
The FDA label says: “Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus; to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular dise...”
What drug class is liraglutide?
FDA lists liraglutide in the GLP-1 Receptor Agonist established pharmacologic class.
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.
More on Liraglutide
- Is Liraglutide a controlled substance?Federal schedule
- Generic for SaxendaFDA Orange Book
- Generic for VictozaFDA Orange Book
- GLP-1 Receptor Agonists listFDA drug class
- Liraglutide Medicare Part D coverageBy plan and state
- NDC 0169-2800Liraglutide NDC record
- NDC 0169-4060Liraglutide NDC record
- NDC 50090-2853Liraglutide NDC record